Laure Elens

List of Publications by Citations

70 papers	2,484 citations	27 h-index	48 g-index
74 ext. papers	3,015 ext. citations	3.8 avg, IF	4.72 L-index

#	Paper	IF	Citations
70	A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. *Clinical Chemistry*, **2011**, 57, 1574-83	5.5	180
69	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. *Therapeutic Drug Monitoring*, **2019**, 41, 261-307	3.2	163
68	The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. *Clinical Pharmacokinetics*, **2014**, 53, 123-39	6.2	150
67	CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. *Pharmacogenomics*, **2013**, 14, 47-62	2.6	142
66	CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. *American Journal of Transplantation*, **2006**, 6, 2706-13	8.7	139
65	Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. *Pharmacogenomics*, **2011**, 12, 1383-96	2.6	119
64	1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. *Pharmacogenetics and Genomics*, **2007**, 17, 873-83	1.9	83
63	Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. *Pharmacogenetics and Genomics*, **2011**, 21, 861-6	1.9	81
62	CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. *Pharmacogenomics*, **2010**, 11, 703-14	2.6	80
61	CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. *Clinical Cancer Research*, **2013**, 19, 3316-24	12.9	72
60	Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. *Clinical Cancer Research*, **2012**, 18, 4433-40	12.9	70
59	The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. *Pharmacogenetics and Genomics*, **2012**, 22, 373-80	1.9	64
58	Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. *Therapeutic Drug Monitoring*, **2014**, 36, 71-9	3.2	62
57	Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. *Therapeutic Drug Monitoring*, **2013**, 35, 608-16	3.2	58
56	Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. *Pharmacogenomics*, **2010**, 11, 1223-34	2.6	48
55	A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. *Clinical Pharmacokinetics*, **2017**, 56, 963-975	6.2	46
54	CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. *Pharmacogenomics*, **2013**, 14, 1027-36	2.6	41

53	CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. *Pharmacogenomics*, **2013**, 14, 137-49	2.6	40
52	Dental Apical Papilla as Therapy for Spinal Cord Injury. *Journal of Dental Research*, **2015**, 94, 1575-81	8.1	33
51	Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. *British Journal of Clinical Pharmacology*, **2014**, 77, 715-28	3.8	33
50	The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. *Pharmacogenetics and Genomics*, **2017**, 27, 313-322	1.9	33
49	The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. *Pharmacogenomics Journal*, **2015**, 15, 144-52	3.5	33
48	ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. *PLoS ONE*, **2014**, 9, e91555	3.7	33
47	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. *British Journal of Clinical Pharmacology*, **2019**, 85, 601-615	3.8	31
46	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. *Frontiers in Pharmacology*, **2017**, 8, 358	5.6	29
45	Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. *Pharmacogenetics and Genomics*, **2013**, 23, 148-55	1.9	29
44	Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2009**, 877, 1805-14	3.2	28
43	The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. *British Journal of Clinical Pharmacology*, **2013**, 75, 1545-7	3.8	27
42	Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. *Pharmacogenetics and Genomics*, **2011**, 21, 884-93	1.9	27
41	Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-δ are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. *Pharmacogenetics and Genomics*, **2013**, 23, 649-57	1.9	26
40	Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. *Pharmacogenomics*, **2014**, 15, 1287-95	2.6	25
39	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. *Therapeutic Drug Monitoring*, **2020**, 42, 360-368	3.2	25
38	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. *Thrombosis Journal*, **2018**, 16, 28	5.6	25
37	Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. *Pharmacogenomics*, **2009**, 10, 1589-97	2.6	24
36	Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. *Scientific Reports*, **2016**, 6, 29559	4.9	23

35	Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. *Pharmacogenomics*, **2014**, 15, 1207-21	2.6	23
34	Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. *Pharmacogenomics*, **2014**, 15, 1589-97	2.6	22
33	A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. *Clinical Cancer Research*, **2013**, 19, 5210-7	12.9	22
32	CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. *Experimental and Clinical Endocrinology and Diabetes*, **2014**, 122, 60-3	2.3	20
31	Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. *Journal of Surgical Research*, **2012**, 178, 988-95	2.5	17
30	Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. *Clinical Chemistry*, **2009**, 55, 170-4	5.5	17
29	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. *Therapeutic Drug Monitoring*, **2021**, 43, 150-200	3.2	17
28	ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. *Pharmacogenomics*, **2016**, 17, 883-90	2.6	16
27	Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement. *Pharmacogenomics*, **2017**, 18, 1133-1142	2.6	15
26	Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?. *Pharmacogenomics*, **2017**, 18, 1473-1480	2.6	15
25	Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. *Molecular Diagnosis and Therapy*, **2012**, 16, 331-45	4.5	15
24	Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction. *Clinical Biochemistry*, **2016**, 49, 580-6	3.5	14
23	No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. *Drug Metabolism and Personalized Therapy*, **2015**, 30, 43-8	2	14
22	POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. *Pharmacogenomics*, **2014**, 15, 1963-72	2.6	14
21	SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. *Therapeutic Drug Monitoring*, **2016**, 38, 487-92	3.2	14
20	Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. *Pharmacogenomics*, **2013**, 14, 1295-304	2.6	12
19	Mycophenolic acid-related anemia and leucopenia in renal transplant recipients are related to genetic polymorphisms in CYP2C8. *Transplantation*, **2012**, 93, e39-40; author reply e41-2	1.8	11
18	Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation. *Therapeutic Drug Monitoring*, **2016**, 38, 525-33	3.2	11

17	Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. *Scientific Reports*, **2018**, 8, 7359	4.9	10
16	Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. *Molecular Diagnosis and Therapy*, **2014**, 18, 323-31	4.5	9
15	Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism. *PLoS ONE*, **2016**, 11, e0165631	3.7	9
14	Association of CYP3A variants with kidney transplant outcomes. *Renal Failure*, **2015**, 37, 562-6	2.9	8
13	Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. *Expert Opinion on Drug Metabolism and Toxicology*, **2020**, 16, 769-782	5.5	7
12	Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines. *Scientific Reports*, **2018**, 8, 10514	4.9	6
11	Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?. *Expert Opinion on Drug Metabolism and Toxicology*, **2018**, 14, 601-611	5.5	6
10	Genotyping in Clinical Practice: Ready for Implementation?. *Frontiers in Genetics*, **2021**, 12, 711943	4.5	5
9	Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype. *Pharmacogenomics*, **2018**, 19, 305-310	2.6	3
8	Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations. *Clinical Pharmacokinetics*, **2021**, 60, 177-189	6.2	3
7	Impact of CYP3A4*22 Allele on Sirolimus Dose Requirement in Kidney Transplant Patients. *Transplantation*, **2012**, 94, 575	1.8	2
6	Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response. *Clinical and Translational Science*, **2021**,	4.9	1
5	Effect of four ABCB1 genetic polymorphisms on the accumulation of darunavir in HEK293 recombinant cell lines. *Scientific Reports*, **2021**, 11, 9000	4.9	0
4	Acute intoxication with nevirapine in an HIV-1-infected patient: clinical and pharmacokinetic follow up. *Aids*, **2009**, 23, 1291-3	3.5	
3	191 Morphine Premedication for Intubation in Preterm Infants - A Pharmacokinetic and Pharmacogenetic Report. *Archives of Disease in Childhood*, **2012**, 97, A55-A55	2.2	
2	Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model. *European Journal of Clinical Pharmacology*, **2021**, 77, 607-616	2.8	
1	Cytochrome P450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. *Pharmacogenomics*, **2018**, 19, 1097-1099	2.6	